Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Life Expectancy With HIV Increases Dramatically
HIV and Aging: The Potential Role of Inflammation
Normal Life Expectancy With Maintenance of CD4s Above 500
HIV Eradication: One Step Closer
Chemical in Bananas May Prevent and Treat HIV
New Hope for HIV Eradication
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

November 13, 2009

HPV Therapeutic Vaccine Works in an Early Trial

A therapeutic vaccine designed to help the immune system better control human papillomavirus (HPV) was nearly 50 percent effective in eliminating precancerous genital lesions, according to a study published November 5 in The New England Journal of Medicine. These encouraging data raise hopes for treating other HPV-related cancers, notably of the cervix and anus.

Currently, two vaccines are approved in the United States to prevent infection with the strains of HPV that can cause cervical and anal cancer: Merck’s Gardasil and GSK’s Cervarix. Neither vaccine, however, has any effect on HPV once a person has become infected with the cancer-causing strains of the virus.

Cornelis Melief, MD, PhD, from the Leiden University Medical Center, in Leiden, the Netherlands, and his colleagues, however, have been working on the development of an HPV vaccine that would hopefully help the body control HPV after a person becomes infected. Melief and his team have developed a proprietary technology for creating synthetic protein segments of HPV and incorporating them into a vaccine. In this case, they designed a therapeutic vaccine against HPV type 16, one of the most common strains known to cause cancer.

Working in Melief’s lab, Gemma Kenter, MD, PhD, and her colleagues gave the vaccine to 20 women—all HIV negative—who had an advanced stage of precancerous lesions on their vulvas, called VIN3. One year after vaccination, 79 percent of the women had measurable regression of their lesions, and 47 percent had complete resolution. The women remained free of lesions for at least two years after vaccination.

The authors acknowledge that further research will be needed in larger numbers of women, and in a controlled study, to determine the vaccine’s efficacy and to gauge its effect on cervical lesions. Clinical trials will also be required to explore the utility of the vaccine in treating precancerous anal lesions, as well as HPV-related lesions in people living with HIV.

Search: HPV, human papillomavirus, therapeutic vaccine, type 16, vulva, cervical cancer, anal cancer, Cornelias Melief, Gemma Kenter


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

       


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

XVIII International AIDS Conference
Vienna, Austria
July 18-23, 2010


17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)
San Francisco, CA
February 16-19, 2010


5th IAS Conference on HIV Pathogenesis Treatment and Prevention (IAS 2009)
Cape Town, South Africa
July 19-22, 2009

more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy